wegovy

Eli Lilly and Co. (NYSE:LLY) on Wednesday released detailed findings from two late-stage obesity studies showing patients were able to maintain significant weight loss after switching from higher-dose injectable incretin therapies to either Foundayo or lower-dose Zepbound. • Eli Lilly stock...

Novo Nordisk A/S (NYSE:NVO) presented new sub-analyses from its STEP UP clinical trial at the European Congress on Obesity, highlighting that a higher dose of Wegovy helped people with obesity achieve substantial weight loss regardless of how quickly they initially responded to treatment. The...

Ulta Beauty Inc. (NASDAQ:ULTA) is benefiting from the booming popularity of GLP-1 weight loss drugs, as users turn to hair and skincare products to address side effects like hair thinning and changes in skin elasticity. GLP-1 Drugs Drive Beauty Product Demand GLP-1 medications such as...

The U.S. Food and Drug Administration (FDA) on Thursday approved a higher-dose version of Novo Nordisk A/S’ (NYSE:NVO) blockbuster weight-loss drug, Wegovy, marking an expansion of its treatment portfolio for adults with obesity. • Novo Nordisk shares are experiencing downward...

The U.S. Food and Drug Administration (FDA) has issued a warning letter to Novo Nordisk A/S (NYSE:NVO), marking another regulatory strike on the pharmaceutical giant over the last six months following a pattern of safety and marketing lapses. Systemic Failures In Safety Data In a letter dated March...

Novo Nordisk A/S (NYSE:NVO) plans to start selling its blockbuster obesity drug Wegovy in vials, marking its latest effort to strengthen its position against rival Eli Lilly and Co. (NYSE:LLY) as competition intensifies in the fast-growing weight-loss market. Currently, Novo markets Wegovy in...

Novo Nordisk A/S (NYSE:NVO) is trading higher on Friday after falling for two consecutive days on lower-than-expected fiscal 2026 guidance and compounding concerns. • Novo Nordisk stock is showing exceptional strength. What’s behind NVO gains? On Tuesday, the company said it expects...

Novo Nordisk A/S (NYSE:NVO) stock is trading lower on Tuesday after the weight-loss drug maker released its 2026 full-year sales and operating profit outlook. 2026 Outlook Novo Nordisk expects reported 2026 sales and operating profit to benefit from a $4.2 billion reversal of 340B Drug Pricing...

Novo Nordisk A/S' (NYSE:NVO) weight-loss revolution just swallowed a record. In just its second week on the market, Novo Nordisk's oral Wegovy pill hit 20,371 prescriptions, up from 4,289 in week one—a nearly 500% week-over-week surge. For context, Eli Lilly And Co's (NYSE:LLY) Zepbound hit about...

The approval of Novo Nordisk's (NYSE:NVO)oral Wegovy is bringing new interest to health care and pharmaceutical ETFs that provide access to the growing GLP-1 market without requiring investors to choose one specific company. • What should traders watch with XLV? Broad funds like the Health Care...

Major U.S. indexes closed higher on Monday, with the Dow Jones Industrial Average rising 0.47% to 48,362.68. The S&P 500 advanced 0.6% to 6,878.49, while the Nasdaq added 0.5% to finish at 23,428.82. These are the top stocks that gained the attention of retail traders and investors through the...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Monday released topline results from its randomized controlled clinical study (VP-VLY-686-2601) evaluating tradipitant to prevent nausea and vomiting induced by Novo Nordisk A/S (NYSE:NVO) Wegovy. • Get the market research on VNDA stock here. The...

Novo Nordisk A/S (NYSE:NVO) announced on Monday that Wegovy (semaglutide) injection 0.25 mg and 0.5 mg and Ozempic are now available at a limited-time price of $199 per month to new self-pay patients between now and March 31, 2026. • NVO is gathering positive momentum. Check the...

Pfizer Inc's (NYSE:PFE) lawsuit. Novo Nordisk A/S' (NYSE:NVO) counterbid. And in the middle of it all — a quiet $45 million position that might turn into Andreas Halvorsen's next masterstroke. After years of fighting from the sidelines of the Ozempic boom, Pfizer is finally throwing punches....

On Monday, major U.S. indexes showed mixed performance — the Dow Jones Industrial Average slipped nearly 0.5% to 47,336.68, while the S&P 500 edged up 0.2% to 6,851.97. The Nasdaq closed 0.46% higher at 23,834.72. These are the top stocks that gained the attention of retail traders and...